A fusion gene containing 5' rat prolactin genomic sequences ligated to the structural portion of the rat growth hormone gene (grl) was introduced by DNA-mediated gene transfer into mammalian cells by using a chimeric plasmid vector. Clonal transfected cell lines produced a mRNA that used the authentic 5' initiation site and that was processed to the predicted size. The intracellular levels of this RNA product were increased 2.5-to 5-fold by exposure of the cells to epidermal growth factor (EGF) and 2-to 3-fold by exposure of the cells to a potent phorbol ester, phorbol 12-myristate 13-acetate, apparently due to regulation at the level of gene transcription. Substitution of the 5' prolactin DNA sequences by 5' growth hormone DNA sequences resulted in the loss of EGF inducibility. A genomic sequence in or near the 5' flanking portion of the prolactin gene therefore appears to confer polypeptide hormone transcriptional regulation upon the gene.
Polypeptide hormones and neuropeptides represent a diverse class of intercellular regulatory substances. They are critical for development and homeostatic control, and they act to regulate the expression of specific genes (e.g., see refs. [1] [2] [3] [4] [5] [6] . To understand the events by which the binding of a peptide hormone to the plasma membrane receptor initiates events that can rapidly (within 1-2 min) modulate gene transcription (4) (5) (6) , it is necessary to define whether a specific genomic sequence is required and sufficient for conferring the effects of polypeptide regulators on gene transcription.
In clonal rat pituitary tumor cell lines (GH) (7) thyrotropin-releasing hormone (TRH), a hypothalamic tripeptide, and epidermal growth factor (EGF), a small polypeptide originally isolated from the submaxillary glands of male mice, increase the production of prolactin (8, 9) and prolactin mRNA (2) (3) (4) (5) . We have demonstrated that both EGF and TRH act at the nuclear level to rapidly increase the transcription of the prolactin gene (5, 6) . In addition, phorbol esters produce effects on GH cells, such as cell shape change, growth alterations, and increased prolactin biosynthesis, similar to those produced by EGF and TRH (10) . We find that phorbol esters increase prolactin mRNA levels, prolactin gene transcription, and phosphorylation of a basic nuclear protein (BRP) in a fashion comparable to the effects of EGF or TRH (5) (6) (7) (8) (9) (10) (11) . Phorbol esters such as phorbol 12-myristate 13-acetate (PMA) appear to directly activate a Ca2'-and phospholipid-dependent protein kinase, referred to as protein kinase C' (12) .
DNA-mediated transfer of regulated eukaryotic genes into heterologous mammalian cells provides the requisite analytic technology for studying the expression and induction of these genes by various regulatory agents outside their normal cellular and chromosomal environment (13, 14) . By using transfectional analysis, it has been demonstrated that DNA sequences located 5' to the so-called "TATA" box and RNA cap site are necessary for efficient and accurate RNA polymerase 11-catalyzed transcription of many eukaryotic genes, in vivo and in vitro (15) (16) (17) . This technology also permitted the evaluation of the hypothesis that specific genomic regions are responsible for hormonal and metabolic regulation of gene expression (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) . Transfer of regulation has been reported in the case of steroid hormones (18) (19) (20) (21) (22) (23) , poly(rI)poly(rC) (24) , and heavy metal (25) regulation of specific genes.
We therefore employed DNA-mediated gene transfer to determine whether specific genomic sequences are required for polypeptide hormone regulation upon responsive genes. A fusion gene containing 5' flanking prolactin genomic information and growth hormone coding regions (grl) was expressed with correct initiation and RNA processing events, in a human cell line rich in EGF receptors. The gene product was induced by the peptide hormone, EGF, apparently exerting transcriptional effects, and by a phorbol ester. Substitution of 5' prolactin genomic sequences with comparable 5' sequences from a nonresponsive gene (growth hormone) abolishes the transfer of hormonal regulation.
METHODS
Cell Culture and DNA Transfection. Human A431 cells were maintained in Dulbecco's modified Eagle's medium containing 1% fetal calf serum. Supercoiled plasmid DNA was introduced into cultured cells by using the calcium phosphate precipitation technique (29) followed by a glycerol shock after 4 hr (30); neomycin-resistant cells were selected by growth in the presence of the antibiotic G418 at 400 ,ug/ml (31) . Individual foci of transformed cells were maintained in the presence of G418 at 200 ,Ag/ml.
Analysis of RNA and DNA. Purified genomic DNA restriction fragments were resolved by electrophoresis of 0.8% agarose gels and then transferred to nitrocellulose by the method of Southern (32) . Total cellular RNA was isolated (2) and DNA was removed by two precipitations with 2 M LiCl/10 mM sodium acetate, pH 5.5 (33) . DNA content of all RNA samples was determined by a fluorometric assay using the DNA dye Hoechst 33258 (34) . Samples (10,g) were analyzed by fractionation using denaturing gel electrophoresis, blotting, and DNA-excess hybridization as described (4 The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. (35) and the S1 nuclease method described by Berk and Sharp (36) . After hybridization with excess labeled DNA probe, the RNADNA hybrids were digested with S1 nuclease and subjected to electrophoresis on denaturing 8% acrylamide/8 M urea sequencing gels (37) . The nuclear run-off transcription assay was performed as previously described (4, 5) using 7 x 107 cpm per hybridization, and growth hormone cDNA was inserted into M13 phage DNA as probe.
RESULTS
Construction of Chimeric Rat Prolactin Genomic Clones for Transfectional Analysis. A simian virus 40 (SV40) hybrid plasmid vector pSV2neo that contained the dominant selectable marker Tn5 phosphotransferase (neo) (31) was modified to contain a fusion gene in which the 5' regions of the growth hormone gene, a gene that is not induced by EGF, were replaced with 5' prolactin genomic sequences (38, 39) in such a way that mRNA transcribed from this gene should contain the information encoded in the first prolactin genomic exon and the second through fifth rat growth hormone genomic exons (see Fig. 1 ). Analysis of the sequences of the first prolactin "donor" splice site and the first growth hormone "acceptor" site showed that they contained the requisite G-T ... A-G sequences under "Chambon" rules of splicing (40) . Therefore, if the prolactin gene contains a regulatory element for EGF induction within or near the 5' nonflanking sequences, the fusion gene (gri) should be productive of an EGF-or PMA-inducible mRNA containing the cap site and 82 nucleotides of prolactin mRNA (exon I) followed by growth hormone mRNA sequences transcribed from exons 2 through 5 of the growth hormone gene. This chimeric genomic construction, designated grl, was inserted into the unique BamHI site of pSV2neo such that the two discrete transcription units, one containing neo (the gene conferring G418 and neomycin resistance), under SV40 early promoter control and adjacent to an enhancer element, and the second, the grl fusion gene, are in opposite transcriptional orientations. A second plasmid, constructed by replacing the Xba I fragment prolactin DNA in the grl gene with the original Xba I fragment of growth hormone, reconstituted the intact rat growth hormone gene (21) .
Organization of the Fusion Gene DNA in Transformed Cells. Human A431 cells were transfected with chimeric plasmids containing either the rat prolactin-growth hormone fusion gene (pSV2ne0grl) or rat growth hormone gene (pSV2ne0GH). Hirt DNA extracts (41) prepared from several of the stable pSV2neogrl-transfected cell lines revealed no extrachromosomal neo or grl DNA. Transfected DNA sequences derived from the chimeric gene were detected in the chromosomal DNA of the transformed cell lines by analysis of HindIII-digested genomic DNA. DNA from the parental A431 cell line shows two strongly hybridizing high molecular weight (>20 kb) HindIII genomic fragments, reflecting endogenous growth hormone genes (Fig. 2) . A unique 5.7-kb HindIII fragment present in the intact plasmid, which spans the entire grl gene, including 5' and 3' flanking sequences, is present in 6 of the 10 pSVneogrl-containing clonal cell lines analyzed, with an estimated chromosomally integrated copy number of 1-4 in different cell lines (Fig. 2) . In one cell line, instead of the 5.7-kb band, a slightly smaller (5.1-kb) band was visualized (grl d). In addition, the cell lines contained a wide variety of additional reactive HindIlI fragments ranging in size from 3.8 to >20 kb (see Fig. 2 ). These heterogeneous fragments are likely to have resulted from integration of the chimeric plasmid DNA at sites within the 5.7-kb HindIII region into variable integration sites of flanking A431 cellular DNA sequences. These data indicate that most lines have multiple integrated copies of both intact and modified grl fusion genes, integrated into a wide variety of genomic sites. One line (grl i) appears to have a single integrated copy of the gene.
RNA Analysis in Transfected Cell Lines. Eight of 10 G418-resistant cell lines analyzed produced the RNA of the size predicted for the product of the fusion gene expression (1 kb) (see Fig. 3 ). RNA prepared from nontransformed A431 cells contained no detectable hybridization to growth hormone cDNA probes. All of the cell lines that contained at least one copy of the intact grl gene produced the authentic 1-kb RNA product of the fusion grl gene (Fig. 3) . The several lines that contained only rearranged grl genomic integrants produced RNAs of inappropriate size, with one exception (grl d). An S1 nuclease resistance assay (36) was used to prove that the RNA product in transfected cell lines was initiated at the 5 correct site, using a 111-bp Pst I fragment of the prolactin gene, which includes the entire 82 bp of exon I and contains 5' and 3' flanking sequences, such that renatured DNA would be larger than DNA protected by formation of RNADNA hybrids (see Fig. 4 ). An excess of the DNA probe was hybridized to the RNA samples from control and EGF-induced cells, and the predicted 82-bp fragment that corresponds to exon I of the authentic rat prolactin gene was protected (Fig. 4) , suggesting that the appropriate initiation site was used in the transcription of the grl gene. No protection was observed when RNA samples from nontransformed A431 cells were substituted in the hybridization reaction.
EGF Stimulates Increase of grI mRNA Levels in Stably Transfected Cell Lines. As shown in Fig. 3A the levels of RNA reactive with growth hormone cDNA from several grltransformed cell lines (a-e) were consistently increased by 2.5-to 5-fold by treatment of the cells with EGF. The kinetics of grI mRNA accumulation in response to hormone induction are shown for one of the cell lines (pSV2neogrl i, Fig.   3A ). An increase in the growth hormone cDNA-reactive RNA can be detected at 6 hr after addition of EGF to cell cultures, with a maximal induction (3.5-fold) at 16-24 hr. There is subsequently a progressive decrease in grl RNA levels; however, even at 48 hr grl RNA remains above the levels observed in untreated cells (Fig. 3B) . A comparison of these data with the EGF induction of authentic prolactin mRNA in GH4 cells shows that the kinetics of prolactin induction in response to EGF are very similar in both cell types, with a tv2 for maximal induction (4-fold) of approximately 7-9 hr in the pSV2n,,grl-transfected cell lines, compared to 5-8 hr in GH cells (Fig. 5) . These data suggest that the kinetics of EGF transcriptional effects and the stabilities of the mature mRNA transcripts are quite similar for the endogenous gene in rat pituitary cells and the transfected fusion gene in a human cell line. S1 nuclease mapping confirmed that EGF induced the accumulation of an mRNA species that used the correct 5' initiation site, protecting the identical 82-nucleotide fragment as authentic prolactin mRNA (Fig. 4) . S1 nuclease resistance analysis revealed that the levels of grl mRNA in clonal pSV2neogrl-transfected cells (pSV2neogrl i) were approximately 1/40ih of the levels of authentic prolactin mRNA in GH4 cells (prolactin mRNA is approximately 1% of the total mRNA in this cell line). Because the neo transcription unit and its adjacent SV40 enhancer element were physically linked to the grl gene in the plasmid used for transfectional analyses, the potential co- plates either mock treated (0) or treated for various times (8, 18, 30, or 48 hr) with EGF and analyzed as described above, using 32p_ labeled growth hormone cDNA (B) or a 32P-labeled Pvu II fragment of the neo gene (C). regulation of the neo gene by EGF was evaluated. The levels of the 1.5-kb neo mRNA remained unaltered, or even slightly decreased, in this and other lines during the time course of EGF treatment (Fig. 3C) (Fig.  6 ). EGF treatment for 24 hr in the identical cell line resulted in a 4.0-fold increase of the fusion gene mRNA. Furthermore, the levels of this RNA species remained at approximately the same levels at the 48 hr time point, in contrast to the attenuation observed after treatment with EGF (Fig. 3B) . The effects of PMA are gene specific, because the levels of neo mRNA in identical RNA samples in which the fusion gene was induced were unchanged between control and EGF or PMA-treated cells (Fig. 6) .
Transcription In the case of polypeptide hormones, which bind to plasma membrane receptors, there has been no conceptual framework by which to explain their rapid (within 1-2 min) effects on specific gene transcription (4-6). Because it is established that modification of specific nuclear proteins widely distributed in chromatin occurs rapidly in response to polypeptide hormones (e.g., see refs. 5 and 42), models that predicted either general alterations in chromatin structures or binding of modified proteins to specific genomic sequences were consistent with available data. The data presented in this manuscript, based upon transfectional analysis of fusion genes, are consistent with the hypothesis that specific 5' prolactin genomic sequences are responsible for conferring EGF regulation upon the prolactin gene and provide the initial evidence for the action of specific 5' genomic regulatory sequences in mediation of polypeptide hormone actions on gene transcription. It should be noted that the A431 cells used in these analyses are actually growth-inhibited by addition of EGF to cultures (43) , an effect that EGF also exerts in GH cells, where it also stimulates prolactin gene transcription. This effect on growth is in contrast to the EGF receptor contents of the two cell lines, which are 2 x 106 and approximately 1-2 x i05 receptors per cell, respectively. In addition, the prolactin gene is transcriptionally regulated by phorbol esters, which appear to activate a Ca2+-and phospholipid-dependent protein kinase, referred to as C' kinase (12) . Because the 5' end of the prolactin gene also transfers regulation by phorbol esters, it is tempting to speculate that both specific genomic sequences and protein modification are requisite for PMA regulation of specific gene transcription.
These data indicate that a human cell line possesses all of the requisite biochemical machinery to transcriptionally regulate a hormonally responsive rat gene (prolactin 5' sequences) and to accurately process the RNA transcripts, suggesting a high degree of conservation between species of the genomic sequences and regulatory molecules that are responsible for polypeptide hormone control of gene expression.
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